Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure

Elke Bouwens, Anne-Sophie Schuurman, Martijn Akkerhuis, Olivier Manintveld, Kadir Caliskan, J van Ramshorst, T Germans, VA Umans, Eric Boersma, Isabella Kardys

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Aim: To investigate the temporal evolution of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) and myeloperoxidase (MPO) in relation to clinical outcome in chronic heart failure (CHF). Methodology & results: Trimonthly blood sampling was performed during a median follow-up of 2.2 (IQR 1.4-2.5) years in 263 CHF patients. Seventy patients reached the primary end point (PE) (cardiovascular death, heart transplantation, left ventricular assist device implantation or HF-hospitalization). MPO level was independently associated with the PE; the adjusted (for clinical factors) hazard ratio (aHR) per standard deviation difference in MPO was 1.71 (95% CI: 1.23-2.43) at any time during follow-up. PCSK9 level (HR: 1.45 [1.04-2.06]) and LDLR (HR: 0.66 [0.49-0.87]) were statistical significantly associated with the PE but only in unadjusted analyses. Slope of temporal MPO evolution (aHR: 1.34 [1.12-1.76] per 0.1 standard deviation/year difference in slope) and LDLR (aHR: 0.78 [0.61-0.90]) however, were associated with PE. Conclusion: Temporal patterns of MPO and LDLR are independently associated with clinical outcome in CHF, which illustrates the importance of assessing temporal evolutions.

Original languageEnglish
Pages (from-to)247-255
Number of pages9
JournalBiomarkers in Medicine
Issue number4
Publication statusPublished - Mar 2021

Bibliographical note

Funding Information:
This work was supported by the Jaap Schouten Foundation and the Noordwest Academie, both nonprofit organizations.

Publisher Copyright:
© 2021 Future Medicine Ltd.

Research programs

  • EMC COEUR-09


Dive into the research topics of 'Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure'. Together they form a unique fingerprint.

Cite this